DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Sledge GW, Toi M, Neven P. et al.
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
JAMA Oncol 2019;
DOI: 10.1001/jamaoncol.2019.4782.
We do not assume any responsibility for the contents of the web pages of other providers.